Keyphrases
Pembrolizumab
100%
Spontaneous Intestinal Perforation
100%
Immune Checkpoint Inhibitors
66%
Programmed Death-ligand 1 (PD-L1)
50%
Life-threatening
33%
Colonic Perforation
33%
Tumor Cells
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Treatment Options
16%
Tumor Burden
16%
Colitis
16%
Immunohistochemical Staining
16%
Older Women
16%
Adverse Events
16%
Full-time Job
16%
Treatment Toxicity
16%
Response Rate
16%
Antibody Targeting
16%
Small Intestine
16%
Response to Treatment
16%
Patient Tumor
16%
Bowel Perforation
16%
Postoperative Day
16%
Hypothyroidism
16%
IrAE
16%
Immune-related Adverse Events
16%
Pathological Findings
16%
Immune Checkpoint Molecules
16%
Partial Response
16%
Primary Anastomosis
16%
Enteritis
16%
Exploratory Laparotomy
16%
Surgical Findings
16%
Predicting Treatment Response
16%
Collective Decision
16%
Stage IV Non-small Cell Lung Cancer
16%
Immune Checkpoint Inhibitor Treatment
16%
Medicine and Dentistry
Intestine Perforation
100%
Pembrolizumab
100%
Immune Checkpoint Inhibitor
83%
Programmed Death 1 Ligand 1
33%
Colon Perforation
33%
Immunotherapy
33%
Neoplasm
16%
Immunity
16%
Adverse Event
16%
Lung Cancer
16%
Treatment Response
16%
Hypothyroidism
16%
Case Presentation
16%
Surgical Anastomosis
16%
Tumor Cell
16%
Colitis
16%
Enteritis
16%
Malignant Neoplasm
16%
Teamwork
16%
Exploratory Laparotomy
16%
Programmed Death 1 Receptor
16%
Cytotoxic T-Cell
16%
Immune-Related Adverse Events
16%